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Human immunodeficiency virus type 1 (HIV-1) Tat transactivates viral genes and is released by infected
cells, acting as a soluble mediator. In endothelial cells (EC), it activates a proangiogenic program by activating
vascular endothelial growth factor receptor type 2 (VEGFR-2) and integrins. A structure-activity relationship
study was performed by functional analysis of Tat substitution and deletion variants to define the Tat
determinants necessary for EC activation. Variants were made (i) in the basic and (ii) in the cysteine-rich
domains and (iii) in the C-terminal region containing the RGD sequence required for integrin recognition. Our
results led to the following conclusions. (i) Besides a high-affinity binding site corresponding to VEGFR-2, EC
express low-affinity binding sites. (ii) The basic and the cysteine-rich variants bind only to the low-affinity
binding sites and do not promote tyrosine phosphorylation of VEGFR-2. Furthermore, they have a reduced
ability to activate EC in vitro, and they lack angiogenic activity. (iii) Mutants with mutations in the C-terminal
region are partially defective for in vitro biological activities and in vivo angiogenesis, but they activate
VEGFR-2 as Tat wild type. In conclusion, regions encoded by the first exon of tat are necessary and sufficient
for activation of VEGFR-2. However, the C-terminal region, most probably through RGD-mediated integrin
engagement, is indispensable for full activation of an in vitro and in vivo angiogenic program.
Tat is one of the regulatory proteins of human immunode-
ficiency virus type 1 (HIV-1). The protein is composed of 86 to
104 amino acids (aa) (according to the viral isolate) encoded by
two exons. In the portion encoded by the first exon (72 amino
acids) four distinct regions can be recognized (N-terminal,
cysteine rich, core, and basic). The second exon encodes the
C-terminal region, containing a RGD sequence (31). Tat plays
an essential role in viral replication by up-regulating viral gene
expression in infected cells by increasing the rates of transcrip-
tional initiation and elongation by DNA polymerase II (31).
Tat also modulates the expression of cellular genes involved in
cell survival and proliferation or in coding for cytokines (11, 12,
23, 29, 37, 41, 54, 63, 66, 69). This newly acquired cell pheno-
type will contribute to the pathogenesis of specific diseases
associate with HIV infection. Besides its intracellular effects,
Tat may alter cellular behavior when it is released by infected
cells in the microenvironment (10, 15). Tat easily enters dif-
ferent cell types contributing to the transactivation of the
HIV-1 long terminal repeat (LTR) promoter in latently in-
fected cells (20, 39). Alternatively, it acts as soluble mediator
affecting the physiologic functions of cells of the immune (30,
35, 43, 49, 66) and nervous (33, 42, 48) systems. Moreover, it
influences the apoptotic program in T cells (26, 36, 41, 65, 70)
and in neurons (47, 59), thus favoring the progression of AIDS
and the associated brain damage.
However, one of the most relevant targets for Tat is the
vascular system, where it activates a proinflammatory and an-
giogenic program. Tat can up-regulate the expression of endo-
thelial cell (EC) adhesion molecules (13, 28), resulting in leu-
kocyte extravasion, which is essential for the homing of
infected lymphomononuclear cells into lymphoid organs and
for the tissue injury characteristic of some features of disease
progression. Alone or combined with inflammatory cytokines,
Tat induces EC to proliferate, release proteolytic enzymes, and
migrate and is fully angiogenic in vivo (1, 3–5, 18). These
features could be relevant to the chronic inflammatory dam-
ages characteristic of several AIDS-associated diseases (17).
Furthermore, the ability of Tat to enter EC during the cell
cycle could favor HIV-1 replication in some EC areas which
are virus reservoirs (44, 45). Finally, Tat participates in the
progression of Kaposi’s sarcoma, both as a growth factor for
spindle cells which represent the core of the tumor and as a
means of sustaining its vascularization (14, 16). Furthermore,
Tat transgenic mice generated by using either the HIV LTR
(63) or the BK polyomavirus promoter (11) develop Kaposi’s
sarcoma-like lesions and tumors of different histotypes, sup-
porting the pathogenetic role of Tat in Kaposi’s sarcoma and in
the vascularization of neoplasms associated with AIDS.
The molecular mechanisms leading to these broad and
pleiotropic activities are largely unknown. By the use of pep-
tides spanning specific domain of the Tat structure or of func-
tional blocking antibodies, some investigators demonstrated
that Tat binding to integrin through the RGD sequence near
the C terminus (7, 62) is relevant for the activation of lympho-
cytes (70), EC (5, 13), monocytes (6, 35), and neuronal cells
(48). Through its N-terminal structure, Tat interacts with
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dipeptidyl peptidase IV, located on the T cell surface, and
suppresses antigen-induced cell activation (26, 68). Addition-
ally, Tat binds to and activates the tyrosine kinase receptors
encoded by the KDR and Flt-1 genes in EC and Kaposi’s
sarcoma cells (4, 21) and monocytes (43), respectively.
We initiated a study of the structure-activity relationship of
Tat to identify functionally important domains that are respon-
sible for the activation of the angiogenic program in vascular
EC. We report here that cysteine-rich and basic domains are
relevant for functional activation of VEGFR-2 whereas the
C-terminal region does not directly participate in the receptor
activation but is required for full cell activation.
MATERIALS AND METHODS
Cells. Human EC from umbilical cord veins, prepared and characterized as
previously described (9), were grown in M199 (Gibco, Grand Island, N.Y.)
supplemented with 20% fetal calf serum (FCS) (Irvine, Santa Ana, Calif.), EC
growth factor (100 mg/ml) (Sigma Chemical Co., St. Louis, Mo.), and porcine
heparin (100 mg/ml) (Sigma). They were used at passage II and grown on a
plastic surface coated with porcine gelatin (Sigma), unless specified.
Tat molecules. Recombinant wild-type HIV-1 Tat of 86 (Tat86) and 101
(Tat101) amino acids were expressed in Escherichia coli as maltose-binding pro-
tein (MBP) or glutathione S-transferase (GST) fusion proteins. They are re-
ferred to below as Tat (MBP-Tat) and *Tat (GST-Tat), respectively. Mutant
constructs were obtained by a recombinant PCR procedure with overlapping
oligonucleotides corresponding to the mutated sequences, and the specific mu-
tations were verified by DNA sequencing. To obtain Tat mutants, a PstI-BamHI
cDNA fragment of Tat86 containing the coding region of both exons was sub-
cloned in the pALTER-Ex1 vector (Promega, Madison, Wis.). Site-directed
mutagenesis was carried out with the Altered Sites mutagenesis kit (Promega) by
using mutant oligonucleotides to introduce specific mutations (Tat D80E, 59
CCC GAG GGG AAC CGA CAG GCC 39; Tat R78K/D80E, 59 CCC GAG
GGG AAC CGA CAG CC 39 and 59 ACC TCC CAA TCC AAA GGG GAA
CCG AC 39; Tat R49G/K50I, 59 CTC CTA TGG CGG GAT CAA GCG GAG
AC 39; Tat R49G/K50I/R52L/R53I, 59 CTC CTA TGG CGG GAT CAA GCG
GAG AC and 59 CGG GAT CAA GCT AAT ACA GCG ACG AAG 39). The
mutated cDNAs (317-bp EcoRI-BamHI fragments) were subcloned into the
pMAL-c2 vector (New England Biolabs, Beverly, Mass.) and expressed as spec-
ified by the manufacturer. Tat86 and its mutants were purified to homogeneity
from bacterial cell lysates by affinity chromatography on amylose resin, as spec-
ified by New England Biolabs, and used as fusion proteins.
*Tat86 and its mutated derivatives including the product of the first exon,
*Tat72, a nonconservative mutant with mutations in basic [*Tat
R(49,52,53,55,56,57)A] and cysteine-rich [*Tat C(22,25,27)A] regions, were pro-
duced as previously described (40), as well as *Tat101 (61). Recombinant fusion
proteins were purified by glutathione-Sepharose affinity chromatography (Sig-
ma) (53). The purified MBP and GST fusion proteins gave a unique band after
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10%
polyacrylamide) and silver staining. Tat86, *Tat86, and *Tat101 and their mutants
were lipopolysaccharide free, as assessed by the Limulus assay (Sigma). Tat and
*Tat were able to induce transcriptional activation of the HIV-1 LTR in HL3T1
cells that contain the bacterial gene of chloramphenicol acetyltransferase (CAT)
directed by the HIV-1 LTR (67). Tat86 and *Tat101 dose dependently stimulated
CAT expression. Briefly, Tat molecules were added to confluent HL3T1 cells in
a 100-mm-diameter dish containing prewarmed phosphate-buffered saline
(PBS). Cells were immediately scraped from the plastic surface, resuspended in
fresh medium, and centrifuged. The cells were again plated in a CO2 incubator,
and a CAT assay was performed after 6 h as described previously (67). Under our
experimental conditions, just scraping of the cells in absence of Tat molecules
had no effect on LTR-directed CAT gene expression (125 6 56 cpm of [3H]acety-
lated chloramphenicol [n 5 3]). However, CAT gene expression was markedly
elevated in cells that received Tat86 at 0.5 mg/ml (423 6 86 cpm of [3H]acetylated
chloramphenicol), 1 mg/ml (2,345 6 167 cpm of [3H]acetylated chlorampheni-
col), or 5 mg/ml (6,543 6 567 cpm of [3H]acetylated chloramphenicol) or *Tat86
at 0.5 mg/ml (512 6 34 cpm of [3H]acetylated chloramphenicol), 1 mg/ml
(3,145 6 343 cpm of [3H]acetylated chloramphenicol), or 5 mg/ml (7,009 6 671
cpm of [3H]acetylated chloramphenicol).
Tat molecules were stored at 280°C in aliquots of 5 mg/10 ml of PBS contain-
ing 0.1% human serum albumin (HSA; Farma Biagini, Lucca, Italy) and 1 mM
dithiothreitol (Sigma).
Iodination of Tat molecules and binding studies. MBP, GST, Tat86, *Tat86,
Tat R78K/D80E, Tat R49G/K50I/R52L/R53I, or *Tat C(22,25,27)A (2-mg sam-
ples) were dissolved in 200 ml of 20 mM sodium phosphate buffer (pH 7.4)
without dithiothreitol and transferred in iodogen-coated tubes (50 mg/ml)
(Pierce Europe B.V., Oud Beijerland, The Netherlands), where proteins were
iodinated (5 min at 4°C) with 0.2 mCi of 125I (Amersham Pharmacia Biotech,
Little Chalfont, United Kingdom). A 20-ml volume of 20 mM phosphate buffer
(pH 7.2) containing 1% HSA, 0.4 M NaCl, and 0.1% 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate (CHAPS; Pierce) was added, and the
reaction products were separated on Sephadex-G10. The specific activities of the
tracers were as follows: MBP, 1 mCi/118 fmol; GST, 1 mCi/134 fmol; Tat86, 1
mCi/108 fmol; *Tat86, 1 mCi/100 fmol; Tat R78K/D80E, 1 mCi/128 fmol; Tat
R49G/K50I/R52L/R53I, 1 mCi/112 fmol; and *Tat C(22,25,27)A, 1 mCi/103 fmol.
[125I]Tat86 and [125I]*Tat86 retained their biological activity on Kaposi’s sarcoma
cells (8).
For binding studies, adherent EC on 24-well plates were incubated for 90 min
at 22°C in 200 ml of M199 containing 20 mM HEPES (pH 7.4), 0.1% HSA, 0.2
U of heparin, 100 mg of soybean trypsin inhibitor per ml, bacitracin (binding
buffer), and increasing concentrations of iodinated Tat molecules or control
proteins in the presence of 100-fold excess of unlabeled proteins. After washes in
buffer binding, the cells were extracted with 2% SDS in PBS. Specific binding
(calculated by subtracting from the total the cpm bound after incubation with a
100-excess of unlabelled ligand) was approximately 80%. Curve displacement
binding was obtained by incubating cells with 0.05 nM [125I]Tat and processed as
described above. Kinetic parameters were estimated with the Ligand program
(Elsevier-Biosoft, Cambridge, United Kingdom).
Immunoprecipitation and immunoblotting. Confluent EC (107 cells/150-cm2
dish) were made quiescent by 20 h of starvation in M199 containing 0.5% FCS
and 0.1% HSA, preincubated for 15 min at 37°C with 1 mM Na3VO4, and then
stimulated as detailed in Results in the presence of heparin (1 U/ml). The cells
were lysed in a 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 1%
Triton X-100, and protease and phosphatase inhibitors (pepstatin, 50 mg/ml;
leupeptin, 50 mg/ml; aprotinin, 10 mg/ml; phenylmethylsulfonyl fluoride, 1 mM;
soybean trypsin inhibitor, 500 mg/ml; ZnCl2, 100 mM, Na3VO4, 1 mM [Sigma]).
After centrifugation (20 min at 10,000 3 g), supernatants were precleared by
incubation for 1 h with protein A-Sepharose or with anti-mouse immunoglobu-
lin-agarose (Sigma). Samples (1 mg of protein) were incubated with rabbit
anti-VEGFR-2 polyclonal antibody (no. C-1158; Santa Cruz Biotechnology, Inc.,
Santa Cruz, Calif.) or antiphosphotyrosine monoclonal antibody (MAb) (clone
G410; Upstate Biotechnology Inc., Lake Placid, N.Y.) (5 to 10 mg/ml) for 1 h at
4°C, and immune complexes were recovered on protein A-Sepharose or anti-
mouse Ig-agarose. Immunoprecipitates were washed four times with lysis buffer,
twice with the same buffer without Triton X-100, and once with Tris-buffered
saline. Proteins were solubilized under reducing conditions, separated by SDS-
PAGE (8 or 10% polyacrylamide), transferred to Immobilon-P sheets (Millipore,
Bedford, Mass.), and probed with antiphosphotyrosine MAb or with anti-
VEGFR-2 antibody. The enhanced chemiluminescence technique (Amersham
Pharmacia Biotech) was used for detection.
PI 3-kinase assay. A phosphoinositide 3-kinase (PI 3-kinase) assay was per-
formed directly on antiphosphotyrosine immunoprecipitates exactly as described
previously (58). Briefly, immunoprecipitates were incubated with 40 mM ATP, 50
to 100 mCi of [g-32P]ATP (Amersham), and a presonicated mixture of phospha-
tidylinositol-4,5-bisphosphate and phosphatidylserine (final concentration of
both lipids, 50 mg/ml [Sigma]) in 25 mM HEPES (pH 7.4)–and 1 mM EGTA.
The reaction was stopped after a 10-min incubation at room temperature by the
addition of 1 volume of 1 M HCl and 2 volumes of chloroform-methanol (1:1).
The lipids in the organic phase were separated by thin-layer chromatography
(Silica Gel 60; Merck, Darmstadt, Germany) in 1-propanol–2 M acetic acid
(65:35, vol/vol) and visualized by autoradiography.
Migration, proliferation, and adhesion assays. EC motility was studied by
using a modified Boyden chamber technique exactly as previously described (9).
To evaluate EC proliferation, 2 3 103 cells were plated in M199 containing
20% FCS in 96-well plates (Falcon, Becton Dickinson Labware, Bedford, Mass.)
coated with gelatin. After 24 h, the medium was removed and replaced with
M199 containing 2.5% FCS. Tat molecules were added on days 0, 2, and 4, and
the cell number was estimated on day 6 as previously described (9).
To study EC adhesion to immobilized Tat molecules, 96-well polysterene
plates (Falcon) were coated overnight at 4°C with Tat molecules or control
proteins (10 mg/well), washed, and then incubated for an additional 2 h at room
temperature with 1% HSA in PBS. Cells were detached in cold PBS containing
2 mM EGTA, washed twice in M199 containing 1% FCS, and plated (5 3 104/0.1
ml) in the adhesion assay. After a 1-h incubation at 37°C, the plates were
extensively washed in M199 containing 1% FCS, fixed, and stained with crystal
violet (9). The absorbance was read at 540 nm in a microtiter plate spectropho-
tometer (EL340; Bio-Tek Instruments, Highland Park, Vt.).
In vivo angiogenesis. Matrigel (Becton Dickinson) supplemented with 10 U of
heparin per ml was mixed with Tat molecules or control proteins and injected
(0.7 ml) into the subcutaneous tissue of BALB/c male mice (Charles River,
Conago, Italy) along the peritoneal midline. After 5 days, the mice were killed
and gels were processed for histology, morphometric analysis, and hemoglobin
content determination measured with a Drabkin reagent kit (Sigma) as previ-
ously described (8).
Statistical methods. One-way analysis of variance (ANOVA) and the Student-
Neuman-Keuls test were used to test the difference within the experimental
blocks of each biological assay. Statistical analyses were performed with STA-
TISTICA for Windows, version 4.5 (StatSoft, Tulsa, Okla.).
VOL. 74, 2000 ENDOTHELIAL CELL ACTIVATION BY HIV-1 Tat 345
RESULTS
Effect of Tat and Tat mutants on biological functions of EC.
It has been reported that soluble Tat induces the activation of
vascular endothelium and of Kaposi’s sarcoma cells through
the engagement of VEGFR-2 (4, 21) and the integrin system
(5, 13, 16). Furthermore, Tat mimics the extracellular matrix
protein and favors cell adhesion through the amino acid se-
quence RGD (7) or the basic domain (62, 64). To examine the
Tat regions involved in EC activation, a set of Tat mutants was
constructed (Fig. 1), expressed as fusion proteins in E. coli, and
studied for their ability to induce cell migration, proliferation,
and adhesion.
First we studied the effect of mutations in the basic region.
Tat R49G/K50I, Tat R49G/K50I/R52L/R53I, and *Tat
R(49,52,53,55,56,57)A had a reduced effect in terms of migra-
tion in the Boyden chamber (Fig. 2) and proliferation (Fig. 3)
of human EC compared to wild-type molecules (Tat86 or
*Tat101) (P , 0.005), with Tat R49G/K50I being more active
than Tat R49G/K50I/R52L/R53I and *Tat R(49,52,53,55,
56,57)A (P , 0.005). Finally, the adhesion of EC to Tat R49G/
K50I/R52L/R53I and *Tat R(49,52,53,55,56,57)A was mark-
edly reduced with respect to the adhesion to Tat86 or Tat
R49G/K50I (P , 0.005) (Fig. 4). These data suggest that the
basic domain is relevant for all the EC biological activities
considered.
Analysis of the mutants with mutations in the RGD se-
quence indicated that this sequence is also necessary for full
activation of the migration (Fig. 2) and proliferation (Fig. 3) of
EC and is required for the adhesion process (Fig. 4). Tat
R78K/D80E showed reduced proliferation and migration ac-
tivities compared to Tat86 (P , 0.005). Tat D80E had an effect
similar to Tat86, indicating that a unique mutation is insuffi-
cient to impair the activities of Tat86 on EC. Deletion of the
sequence encoded by exon 2 (*Tat72) resulted in a molecule
with biological activities (migration and proliferation) similar
to those of Tat R78K/D80E (Fig. 2 and 3). Similarly, *Tat72
and Tat R78K/D80E were not permissive for EC adhesion
(Fig. 4).
*Tat C(22,25,27)A, the mutant with the mutation in the
cysteine-rich region, was a weak activator of EC migration and
proliferation and showed little impairment of the adhesive
property (Fig. 2 to 4). This suggests that the cysteine-rich
region of Tat is required for migration and proliferation of EC
rather than for their adhesion to the extracellular matrix.
In an effort to better define the activation of EC by the
different Tat domains, the migration of EC was triggered by
different concentrations of Tat86, Tat R49G/K50I/R52L/R53I,
Tat R78K/D80E, and *Tat C(22,25,27)A. All concentrations of
the mutants tested (5 to 100 ng/ml) showed a reduced activity
compared to Tat86. However, the highest concentrations of Tat
R78K/D80E (50 to 100 ng/ml) tended to reach the activity of
Tat86 (Fig. 5).
MBP and GST, the two proteins fused to the different Tat
molecules used, did not promote migration, proliferation, or
adhesion at any concentration tested (0.1 to 200 ng/ml) (Fig. 2
to 4).
In vivo effect of Tat and Tat mutants in an angiogenesis
model. The capacity of Tat to induce migration and prolifera-
FIG. 1. Domain structure of the HIV-1 Tat protein and mutations introduced. The arbitrary domain structure is that of Kuppuswamy et al. (34). The number of
mutated amino acids is indicated.
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tion of EC has as in vivo counterpart, i.e., the formation of new
blood vessels in rabbit and mouse models (3, 4). Analysis of the
effects of Tat mutants in a murine angiogenesis assay is re-
ported in Table 1. Progressive mutations in the basic region or
in the RGD sequence were associated with an increasing loss
of angiogenic activity compared to the effect of wild-type mol-
ecules (Tat86 or *Tat101). The deletion of the amino acids
encoded by exon 2 of tat led to negligible angiogenic activity.
Also, the mutation in the cysteine-rich region did not promote
angiogenesis. Overall, the in vivo data clearly indicate that the
angiogenic program elicited by Tat is dependent on the mo-
lecular integrity of its basic and cysteine-rich domains as well as
that of the exon 2 product.
Binding of Tat and Tat mutants to EC. We have previously
demonstrated that EC express high-affinity binding sites for
Tat, identified as VEGFR-2 (4). In this study we used a large
amount of [125I]Tat86 with high specific activity, which permit-
ted us to study also the presence of low-affinity binding sites on
EC. The binding of Tat was evaluated by using saturation
binding curves and by competitive displacement of [125I]Tat86.
The direct ligand binding curves suggested that Tat binding
approached saturability without reaching full saturation. Scat-
chard analysis suggested the presence of two classes of binding
sites. Besides a high-affinity binding site (Kd 5 15.7 6 5.3 pM;
Bmax 5 31.9 6 7.2 fmol [n 5 3]), a low-affinity (Kd 5 8.5 6 3.2
nM; Bmax 5 2.6 6 1.4 pmol [n 5 3]) and high-capacity binding
site was also observed (Fig. 6; Table 2). The competitive dis-
placement experiments of [125I]Tat86 with increasing amounts
of cold ligand confirmed the presence of two binding sites
(Table 2).
By using Tat mutants, we examined the regions of Tat re-
quired for binding to EC. Saturation binding curves of [125I]Tat
R49G/K50I/R52L/R53I and of [125I]*Tat C(22,25,27)A (Fig.
6) as well competitive displacement of [125I]Tat86 with the two
unlabeled peptides (Table 2) indicated that these mutants
bound EC only with low affinity. The number of low-affinity
sites bound by [125I]Tat R49G/K50I/R52L/R53I and [125I]*Tat
C(22,25,27)A was increased compared to that bound by
[125I]Tat86 (Table 2). The same experimental approaches
showed that Tat R78K/D80E bound endothelium in almost the
same manner as did Tat86 (Fig. 6; Table 2). [
125I]MBP and
[125I]GST did not show any specific binding to EC, and the
unlabeled proteins were unable to displace [125I]Tat (data not
shown).
Effect of Tat and Tat mutants on VEGFR-2 phosphorylation
and signal transduction. Figure 7 shows the tyrosine phos-
phorylation of VEGFR-2 immunoprecipitated from EC stim-
ulated with Tat86 and different Tat variants. Tat86, *Tat72, Tat
R78K/D80E, and TatD80E induced the phosphorylation of
VEGFR-2. Moreover, we consistently observed that Tat
R78K/D80E phosphorylated the receptor more efficiently than
Tat86 did. In contrast, mutants with mutations in the basic
domain [(Tat R49G/K50I, Tat R49G/K50I/R52L/R53I, and
*Tat R(49,52,53,55,56,57)A] showed a reduced ability to phos-
phorylate the receptor. This feature depends on the number
of basic residues mutated, with Tat R49G/K50I being more
active than Tat R49G/K50I/R52L/R53I and *Tat R(49,52,53,
55,56,57)A. These data confirm that the binding and activation
of VEGFR-2 are mediated by the basic domain, while the
RGD sequence seems to be not involved in receptor phosphor-
ylation. Mutations in the cysteine-rich region [*Tat C(22,25,
FIG. 2. Effect of Tat molecules on the migration of EC. The migration of EC
across a 5-mm-pore-size polycarbonate filter in response to Tat molecules (20
ng/ml) or vehicle was evaluated by using a Boyden chamber. At the end of the
incubation (37°C for 6 h), the filters were removed and stained and five high-
power oil immersion fields were counted (4003 magnification). Results (mean
and standard deviation) of one experiment (performed in triplicate) represen-
tative of at least three independent experiments are shown. Data were analyzed
by ANOVA (F 5 41.11) and the Student-Newman-Keuls test. p indicates P ,
0.05 within Tat-stimulated EC and unstimulated or control protein-stimulated
cells; § indicates P , 0.005 within wild-type Tat molecule-stimulated EC and Tat
mutant-stimulated cells.
FIG. 3. Effect of Tat molecules on EC proliferation. A total of 2 3 103 EC
were plated in 96-well plates and grown for 12 h in M199 containing 20% FCS.
After 24 h, the medium was removed and replaced with M199 containing 2.5%
FCS. Tat molecules (20 ng/ml) were added on days 0, 2, and 4, and the cell
number was estimated on day 6. Cells were fixed and stained with crystal violet,
and the absorbance was read at 540 nm. Results (mean and standard deviation)
of one experiment (performed in quadruplicate) representative of at least four
independent experiments are shown. Data were analyzed by ANOVA (F 5
86.31) and the Student-Newman-Keuls test. p indicates P , 0.05 within Tat
molecule-stimulated EC and unstimulated or control protein-stimulated cells; §
indicates P , 0.005 within wild-type Tat molecule-stimulated EC and Tat mu-
tant-stimulated cells.
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27)A] also abrogated the ability of Tat to promote VEGFR-2
phosphorylation. MBP and GST did not phosphorylate
VEGFR-2 (Fig. 7).
It has been recently demonstrated that PI 3-kinase activation
is associated with the signals elicited by VEGFR-2 activation
elicited by VEGF-A and Tat86 (25, 58). To support the notion
that the basic domain of Tat86 is involved in the signalling
pathways downstream of VEGFR-2, we tested the activity of
PI 3-kinase in EC stimulated with Tat R49G/K50I/R52L/R53I
and Tat R78K/D80E. The results reported in Fig. 8 show that
Tat R49G/K50I/R52L/R53I activated PI 3-kinase activity to a
lesser extent than Tat86 or Tat R78K/D80E did.
DISCUSSION
HIV-1 Tat is essential for viral replication in infected cells
and acts as a soluble mediator in the microenvironment. Sev-
eral studies on the structure-activity relationship of Tat have
determined the domains involved in gene transcription. The
basic domain (aa 49 to 57) mediates the binding of Tat to
trans-activation element RNA (22, 27), directs it to the nucleus
(27, 52), and is essential for the recruitment of the p300/CBP
transcriptional coactivator (40). A cluster of acidic residues
(Glu2, Asp5, and Glu9) in the proline-rich domain, the cys-
teine-rich domain (aa 22 to 37), and the core domains (aa 32 to
47) all contribute to LTR-directed transcriptional activation
(22, 38, 51, 52, 56). More recently, it has been reported that the
C-terminal domain encoded by exon 2 also makes a small
contribution to viral replication (60).
In this study we have analyzed Tat mutants for binding to
and activation of EC, which are among the more relevant
extracellular targets for this viral protein (1, 3–5, 13, 18, 28).
In a previous work (4), we detected only a high-affinity
binding site corresponding to VEGFR-2, as demonstrated by
the ability of VEGF-A to displace [125I]Tat. However, it has
been recently demonstrated that Tat binds to heparan sulfate
(3, 53) and to integrins (7, 62) that both have features of
low-affinity, high-capacity binding sites. Therefore, we have
revised these binding studies by using larger amounts of
[125I]Tat than in our previous study, labeled at high efficiency.
Under these experimental conditions, we detected two binding
FIG. 4. Effect of immobilized Tat molecules on adhesion of endothelial cells.
A plastic surface was coated overnight at 4°C with Tat molecules or control
proteins (10 mg/well) and then saturated with 1% HSA. Suspended cells (5 3
104/0.1 ml) were seeded, and after a 1-h incubation at 37°C, plates were exten-
sively washed in M199 containing 1% FCS, fixed, and stained with crystal violet.
The optical density (O.D.) was read at 540 nm in a microtiter plate spectropho-
tometer. Results (mean and standard deviation) of one experiment (performed
in quadruplicate) representative of at least four independent experiments are
shown. Data were analyzed by ANOVA (F 5 71.16) and the Student-Newman-
Keuls test. p indicates P , 0.05 within Tat molecule-stimulated EC and unstimu-
lated or control protein-stimulated cells; § indicates P , 0.005 within wild-type
Tat molecule-stimulated EC and Tat mutant-stimulated cells.
FIG. 5. Dose-dependent effect of Tat86 (F), Tat R49G/K50I/R52L/R53I (.),
TatR78K/D80E (), and *Tat C(22,25,27)A (E) on EC migration. The cell
migration was studied by the Boyden chamber technique as described in the
legend to Fig. 1. The data obtained with *Tat86 have not been reported as
superimposable on those obtained with Tat86. Results (mean and standard de-
viation) of one experiment (performed in triplicate) of two are shown.
TABLE 1. Quantitative analysis of the angiogenic
effect of Tat moleculesa
Conditions
No. of positive
implants/total
no. of
implanted
Matrigel
plugsb
Morphometric
result (% of the
total Matrigel area
that is vascularized)c
1. Control 3/13 6 6 3
2. Tat86 10/11 56 6 7
3. Tat72 2/7 13 6 3
4. *Tat101 3/3 56 6 13
5. Tat D80E 4/4 49 6 8
6. Tat R78K/D80E 3/9 5 6 3
7. Tat R49G/K50I 9/13 36 6 9
8. Tat R49G/K50I/R52L/R53I 1/8 7 6 8
9. *Tat C(22,25,27)A 1/5 11 6 7
10. MBP 1/5 9 6 7
11. GST 1/5 8 6 3
a Matrigel (0.5 ml) containing 10 U of heparin per ml was mixed with factors,
and the angiogenic response was evaluated after 4 days by measurement of the
hemoglobin content and morphometric analysis done on hematoxylin-eosin-
stained histological sections (4).
b Implants were considered positive with a hemoglobin content $0.2 g/dl. R 3
C tables of contingency gave a x2 of 58.66 with P , 0.05.
c Morphometric analysis was performed on four representative implants for
each group. Results are mean 6 standard deviation. One-way ANOVA gave F 5
39.62 with P , 0.0001. The Student-Newman-Keuls test gave a P , 0.05 in 1
versus 2, 4, 5, and 7; 2 versus 3, 6, 7, 9, 10, and 11; 3 versus 4, 5, and 7; 4 versus
6, 7, 8, 9, 10, and 11; 5 versus 6, 7, 8, 9, 10, and 11; 6 versus 7; and 7 versus 8, 9,
10, and 11.
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FIG. 6. Specific binding at equilibrium and Scatchard plot of [125I]Tat86 (A and B), [125I]Tat R78K/D80E (C and D), [125I] Tat R49G/K50I/R52L/R53I (E and F),
and [125I] *Tat C(22,25,27)A (G and H) to EC. Monolayers (105 cells) were incubated for 90 min at 22°C with the indicated concentrations of iodinated molecules in
the presence of a 100-fold excess of cold ligands. Results of one experiment of three are shown. Tat86: Kd (site 1) 5 12.9 pM; Bmax (site 1) 5 28.9 fmol; Kd (site 2) 5
4.21 nM; Bmax (site 2) 5 1.32 pmol. Tat R78K/D80E: Kd (site 1) 5 23.8 pM; Bmax (site 1) 5 38.4 fmol; Kd (site 2) 5 13.2 nM; Bmax (site 2) 5 1.50 pmol. Tat
R49G/K50I/R52L/R53I: Kd (site 1) 5 4.58 nM; Bmax (site 1) 5 3.51 pmol. *Tat C(22,25,27)A: Kd (site 1) 5 1.15 nM; Bmax (site 1) 5 1.39 pmol.
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sites for Tat on the surface of EC. The presence of MBP did
not interfere with the binding, because it did not show any
specific binding to the cells and did not displace [125I]Tat. The
Kd of the first was in the picomolar range, and that of the
second was in the nanomolar range. We can hypothesize that
this low-affinity site reflects the binding of Tat to membrane
glycosaminoglycans and/or to integrins.
To elucidate the functional importance of the basic domain
of Tat, two, four, or six nonconservative mutations were made.
Variants with a double mutations exhibited only a slightly
reduced activity compared to Tat86 or Tat101 in term of migra-
tion, proliferation, and adhesion of EC and of angiogenesis
induction. However, the variants with four or six substitutions
showed a marked decrease in the activities studied. Because
Tat signals inside the cells through the tyrosine kinase
VEGFR-2 (4, 21, 58), we investigated the tyrosine phosphor-
ylation of VEGFR-2. Tat R49G/K50I/R52L/R53I and *Tat
R(49,52,53,55,56,57)A failed to activate the receptor. Tat
R49G/K50I induced VEGFR-2 phosphorylation but to a lesser
extent. The variants with two or four mutations did not activate
PI 3-kinase, which is downstream of Tat86 and VEGF-A-acti-
vated VEGFR-2 (58). These results are in agreement with the
similar observations obtained with a peptide encompassing the
basic domain, which mimics the effect of Tat86 on VEGFR-2
(4, 21). The variant with four mutations did not retain the
ability to bind to the high-affinity sites on EC, which corre-
spond to VEGFR-2 (4). Taken together with the previous data,
this suggests that the Tat basic domain is crucial for the binding
and activation of VEGFR-2. The relevance of the positively
charged amino acids in performing these functions is consis-
tent with the observation that the charged residues R82, K84,
and H86 of VEGF-A are important for VEGFR-2 recognition
(32).
To ascertain whether the RGD sequence is required for Tat
binding or activity, mutants with single (D80E) and double
(R78K/D80E) mutations and a variant truncated after the res-
idue 72 (Tat72) were obtained. Tat R78K/D80E and Tat72 had
reduced biological activity in vitro and in vivo, which is consis-
tent with previous reports showing that avb3-, avb5-, and a5b1-
integrin participate in Tat-induced activation of EC (5, 13) as
well as of other cell types (6, 7, 35, 48, 62, 70). Moreover, the
RGD sequence and the C-terminal domain are not required
for VEGFR-2 activation, as shown by the ability of Tat R78K/
D80E and Tat72 to induce VEGFR-2 phosphorylation. Fur-
thermore, the variant with the double mutations activated PI
3-kinase activity and retained the ability to bind both low- and
high-affinity Tat binding sites on the EC membrane. In our
experiments, we have observed that the activity of Tat R78K/
D80E on VEGFR-2 phosphorylation was greater than that
elicited by Tat86. The explanation of this result is lacking, but
it will be interesting to determine the role of VEGFR-2 regu-
latory pathways associated with integrins. For instance, we
have recently shown that b3-integrin is associated with VEGF-
FIG. 7. Effect of Tat molecules on tyrosine phosphorylation of VEGFR-2.
Quiescent, confluent EC were preincubated for 15 min at 37°C with 1 mM
Na3VO4 and then stimulated with Tat molecules (20 ng/ml) for 10 min. The cells
were lysed and immunoprecipitated with anti-VEGFR-2 antibody. The immu-
noprecipitate was analyzed by SDS-PAGE followed by immunoblotting with
antiphosphotyrosine MAb. Subsequently, the blots were reprobed with anti-
VEGFR-2 antibody. Immunoreactive bands were detected by enhanced chemi-
luminescence. The results are representative of three similar experiments.
FIG. 8. Effect of Tat molecules on PI 3-kinase in endothelial cells. Quiescent,
confluent ECs were stimulated with Tat molecules (20 ng/ml) for 15 min at 37°C.
The PI 3-kinase assay was performed on immune complexes done with MAb
antiphosphotyrosine (anti-PY) antibodies from lysates of EC in the presence of
40 mM ATP, 50 mCi of [g-32P]ATP, and 50 mg of a presonicated mixture of
phosphatidylinositol-4,5-bisphosphate and phosphatidylserine per ml in 25 mM
HEPES (pH 7.4)–1 mM EGTA. The extracted lipids were separated by thin-
layer chromatography and visualized by autoradiography. PIP3, phosphatidylino-
sitol-3,4-bisphosphate; Prot-A, a PI 3-kinase assay done on protein A alone.
Spots corresponding to PIP3 were recovered and counted (n 5 3): control, 420 6
132 cpm; Tat86, 1,342 6 231; Tat R78K/D80E, 1,280 6 280; Tat R49G/K50I/
R52L/R53I, 750 6 201. I.P., immunoprecipitate.
TABLE 2. Binding affinity of Tat molecules to EC
Protein
High-affinity sitesa Low-affinity sitesa
Kd
b (pM) Bmaxb (fmol) IC50c (pM) Kdb (nM) Bmaxb (pmol) IC50c (nM)
Tat86 15.7 6 7.3 31.9 6 7.2 12.3 6 7.1 8.5 6 3.2 2.6 6 1.4 17.0 6 6.2
Tat R78K/D80E 25.6 6 1.6 4.6 6 1.2 10.2 6 4.1 11.2 6 4.3 4.3 6 2.1 8.5 6 3.2
Tat R49G/K50I/R52L/R53I NDd ND ND 5.6 6 2.1 5.5 6 2.4 12.3 6 6.3
*Tat C(22,25,27)A ND ND ND 4.8 6 2.8 3.1 6 0.2 10.7 6 3.5
a Mean 6 standard deviation of three experiments.
b Calculated from binding-affinity curves.
c Calculated from displacement binding curves.
d ND, not done.
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A-stimulated VEGFR-2 and that a MAb against this integrin
inhibits the activation of the receptor (58). Alternatively, this
variant can assume a spatial conformation more favorable for
receptor activation, independent of the interaction with inte-
grins. Therefore, the activation of the biological activities of
EC related to angiogenesis most probably requires the engage-
ment of VEGFR-2 as well as integrins by two specific molec-
ular determinants of Tat: the basic domain and the product of
exon 2 containing the RGD motif. Many of the integrin-in-
duced signalling pathways are also normally activated by bind-
ing of soluble growth factors to their receptors, which suggests
the existence of coordinate mechanisms between integrins and
growth factors in the control of cell functions, and there is
increasing evidence that growth factors can induce an appro-
priate cellular response only when the target cells express de-
fined sets of integrins (24, 55). Normally, growth factors do not
directly bind to and activate integrin. The data reported here
and those showing that anti-avb3 or anti-VEGFR-2 neutraliz-
ing antibodies (4, 5, 58) inhibit the EC response to Tat suggest
that this viral protein is a unique example of a molecule which
turns on intracellular signals by direct activation of both re-
ceptor and integrin systems. Furthermore, besides playing a
direct role in integrin activation, the C terminus region of Tat
could regulate VEGFR-2 through the presence of other de-
terminants relevant for the engagement of neuropilin-1, a co-
receptor of this tyrosine kinase receptor (57).
*Tat C(22,25,27)A was used to study the role of the cysteine-
rich region of Tat in EC activation. This variant was less potent
than Tat86 or Tat101 in terms of migration, proliferation, ad-
hesion, and in vivo angiogenesis, bound only the low-affinity
binding site, and showed low efficiency in VEGFR-2 phosphor-
ylation. Because it has been suggested that Tat forms a dimer
bridging cysteine-rich regions from each monomer (19) and
that two cysteine residues are pivotal for the VEGF-A dimer-
ization and the subsequent binding to and activation of endo-
thelium (46, 50), it could be hypothesized that the active form
of Tat on the endothelium has a dimeric structure. The rele-
vance of this domain has also been emphasized by Albini et al.,
who demonstrated its role in the migration of monocytes (2).
Except for Tat D80E, all mutants studied showed a reduced
ability to activate EC functions, but their effects are only par-
tially overlapping. For example, mutants with mutations in the
RGD sequence have reduced biological activities but fully ac-
tivated VEGFR-2 phosphorylation. Tat R49G/K50I promoted
cell adhesion as Tat86, but its migratory and proliferative ca-
pacities were consistently lower than those of Tat86. Mutants
with mutations in basic and in cysteine-rich domains had sim-
ilar kinetic binding parameters, which differed from those of
TatR78K/E80D. Furthermore, Tat E80D was similar to Tat86
or *Tat101 in all assays performed. Taken together, these ob-
servations exclude the possibility that the effects of the Tat
mutants are caused merely by an unfolded protein, as also
reported for other studies performed with Tat mutants (22, 27,
38, 40, 51, 52, 56, 60).
In conclusion, this study demonstrates that the product of
the first exon of tat is crucial for the activation of VEGFR-2
and for induction of the activation of an angiogenic program in
EC. However, to obtain full activation of this program, Tat also
requires the C-terminal region containing the RGD sequence.
The C-terminal region could influence the VEGFR-2 response
by interacting with integrin subunits or with neuropilin-1 (57),
which modulate the functions of this tyrosine kinase receptor,
or with other unidentified coreceptors. Further studies of the
hypothesized role of Tat dimerization by intermolecular cys-
teine bridge formation should make it possible to define the
receptor-ligand interaction more precisely.
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ADDENDUM IN PROOF
Boykins et al. (R. A. Boykins, R. Mahieux, U. T. Shanka-
varam, Y. S. Gho, S. F. Lee, I. K. Hewlett, L. M. Wahl, H. K.
Kleiman, J. N. Brady, K. M. Yamada, and S. Dhawan, J. Im-
munol. 163:15–20, 1999) recently reported that a peptide con-
taining six cysteine residues (from amino acids 21 to 40 of the
Tat molecule) is angiogenic in chicken chorioallantoic mem-
branes.
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